Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

DURVALUMAB for Neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 253 adverse event reports in the FDA FAERS database where DURVALUMAB was used for Neoplasm malignant.

Most Reported Side Effects for DURVALUMAB

Side Effect Reports % Deaths Hosp.
Death 2,817 16.4% 2,816 98
Malignant neoplasm progression 1,330 7.8% 343 166
Pneumonitis 827 4.8% 221 333
Radiation pneumonitis 786 4.6% 112 343
Pyrexia 573 3.3% 79 372
Diarrhoea 530 3.1% 99 267
Pneumonia 453 2.6% 169 300
Dyspnoea 444 2.6% 113 215
Interstitial lung disease 430 2.5% 144 220
Off label use 395 2.3% 70 102
Fatigue 367 2.1% 57 102
Rash 359 2.1% 43 94
Neutrophil count decreased 343 2.0% 49 76
Asthenia 326 1.9% 104 121
Colitis 319 1.9% 73 164

Other Indications for DURVALUMAB

Non-small cell lung cancer (3,396) Hepatocellular carcinoma (1,255) Small cell lung cancer (1,063) Bile duct cancer (972) Non-small cell lung cancer stage iii (840) Small cell lung cancer extensive stage (660) Lung neoplasm malignant (641) Pancreatic carcinoma (584) Cholangiocarcinoma (444) Pancreatic carcinoma metastatic (184)

Other Drugs Used for Neoplasm malignant

PALBOCICLIB (1,996) CAPECITABINE (1,493) PEMBROLIZUMAB (1,135) PACLITAXEL (984) CARBOPLATIN (977) NIVOLUMAB (947) OXALIPLATIN (823) PAZOPANIB (716) CYCLOPHOSPHAMIDE (685) FLUOROURACIL (676)

Related Pages

DURVALUMAB Full Profile All Neoplasm malignant Drugs DURVALUMAB Demographics DURVALUMAB Timeline